In our recent studies, we targeted EphA2 in pancreatic cancer with agonistic agents and demonstrated that suppression of EphA2 significantly reduced cancer-cell migration in cell-based assays. This evidence concerns the gene EPHA2 and familial pancreatic carcinoma.